EUropean CanCer Org. (KC)
From Kidney Cancer Resource
Contents |
EUropean CanCer Org. on Kidney Cancer
To view the web site Home Page of The EUropean CanCer Organisation (ECCO) Click Here
Overview
Details
Articles
26-Sep-2007 - Experimental drug shows promise in advanced kidney cancer
Press releases
Experimental drug shows promise in advanced kidney cancer
source: ECCO 14
Experimental drug shows promise in advanced Kidney Cancer
Barcelona, Spain: A new drug has shown promise in patients with advanced Kidney Cancer whose options run out after their Tumour fails to respond to the cutting edge therapy.
The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, Axitinib, shrank Tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.
In the study, scientists gave Axitinib to 62 patients whose Kidney Cancer had spread and who had not benefited from a standard treatment, Sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the Tumour’s ability to form new blood vessels that help it grow. Fourteen of the patients also had been given – to no avail – another similarly targeted drug, Sunitinib, after the Sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.
“More than half the patients – 51 percent – experienced Tumour shrinkage and in 23 percent of them the shrinkage is considered significant,” said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. “Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to Axitinib.
The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,” Rini added. The study found the tumour remained stable in 37 percent of the patients.
“Historically, metastatic Kidney Cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that Axitinib is a very active drug in Renal Cell Cancer that can benefit a large number of patients,” Rini added.
The drug’s maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.
Catalogue no: 4507
To view the original of this article Click Here
Comments
COMMENTS
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
